Shareholders update!
A summary of conversation with management
Cryogenics will be revamping its sight to assist in simplifying the
understanding of their technology. They will also give investors the
ability to sign up to receive company updates pertinent to the continual
progress. As per my conversation with CYGS last Thursday, it's becoming
more evident that CYGS has gone through extensive lengths to facilitate
progress and prepare for the future. It was also evident that they are
very excited about the future of the company and there was much that
wished to be expressed but could not go into further detail at this time.
Progress and forthcoming developments
The alliance with CYGS and PCCA PharmGenix™
CYGS has recently re-located to a 125,000 Sq.ft facility, which allows
them to take a more progressive stance in their research and development.
This facility joins PCCA within close proximity of each other allowing the
company's team of scientist to Enhance the efficiency of in-house testing
with PCCA's team of scientist in a joint alliance to form
PharmaGenix™.This is a big step in facilitating the collaborated efforts
of securing a revenue stream for the company. Cyrogenics Solutions has
worked diligently towards the completion of the “ Pharmagenix deal “ It is
expected to be completed in the near future. In association with the
completion of PharmaGenix™, additional sub-licensing agreements as well as
other commercial licensing possibilities exist. Shareholders can expect a
press release in regards to the development and/or finality of this
project. Management is very optimistic in regards to the completion of
PharmaGenix™ .
The joint alliance of PharmaGenix is described as a synergistic
opportunity by which CYGS will license its proprietary single stranded
DNA intracellular expression vector (ssDNAev) technology to PharmaGenix™.
PharmaGenix™ is the gateway from which their ingredients in combination
with CYGS's technology are prepared as customized prescriptions. PCCA's
2,500 members of compounding pharmacies will in turn serve over 100,000
physicians which can then meet the needs of their patients. This project
is nearing completion.
Within the entity of PharmaGenix™ . CYGS and PCCA exist as a cooperative
corporate enterprise, which will link traditional pharmacology with
molecular biology to provide personalized healthcare products for the 21st
Century. This alliance represents a progressive stance towards securing
the future role of gene therapy in the evolution of modern health care.
ISSUANCE OF PATENTS
CYGS has confirmed the exception of some Patents that were submitted for
registration. They had expected to release developments to that effect but
are awaiting the official recognition that would make it possible for
shareholders to confirm it's existence through public regards. We expect
further details to become public upon official completion in the near
future.
LICENSCING DEAL WITH MAJOR BIO-MED COMPANY
The question of licensing deal with a major NASDAQ company was confirmed
at the December 16 shareholders meeting. The company voluntarily
reiterated that fact and expressed that the deal is indeed still in the
works and “ is coming to a head soon! “They also expressed that attorneys
on both sides where hard at work and that the situation “looks good”. This
will be announced to shareholders in the form of a press release.
PUBLICATION OF MANUSCRIPT
The publication of a manuscript from University studies is in the final
stages of submission to a peer- reviewed journal. It is expected to be
accepted !!!!!
I neglected to ask if these were conclusive studies of one or several of
the universities that requested beta test kits from the company beginning
in April of 1999. There are numerous high profile universities that have
been licensed to test CYGS's single-stranded DNA expression vector. The
publication of its successful use will grant CYGS significant exposure in
the industry. CYGS has conclude success of its vector in it's own testing
and is awaiting conclusive results from universities for subsequent
submission to industry journals as well.
ADDITIONAL TESTING FOR MORE PROGRESSIVE APPLICATIONS
CYGS expressed that a series of specific test in regards to their
technology has evolved to a higher level but that they could not expand on
the details at this time. From my past conversations with members of
management, I could reasonably speculate that the next level would involve
prime mates studies for the purpose of testing more progressive aspects of
the successful application of CYGS's technology. This is a significant
step, which upon successful completion could open the doors to humane
trials for the testing various aspects of the application of their
technology. This is a vital step towards the commercial applications of
such technologies, many of which never make it through the fundamental
trials of basic laboratory testing. As with all test phases for the
refinement of such technologies, progress proceeds at its own pace.
However, through my individual research of laboratory testing of gene
therapy and Antisense drugs, CYGS has made major headway to even consider
a next phase of testing that includes prime mates as subjects. We will
keep shareholders briefed on any developments that the company wishes to
confirm at the first available opportunity.
CYGS CONFERENCE “OLIGO” ANNOUNCEMENT
CYGS will have a major press releases in regards to a conference which
will demonstrate the elements of progress and application of their
technology. This conference will cater to scientist and professionals in
the industry and is the stepping-stone to additional licensing of their
technology to owners of patented gene sequences.
The companies developments is coming in line with their ultimate goal in
addressing the solution. CYGS's progress in addressing the industry's
barrier is best described from an excerpt from their web site :
The Solution : cygs.net
The CYGS stem loop vector merges the above antisense approaches. This new
technology allows an expression vector to target cells, enter the cell,
and replicate if desired. The vector cassette, when inserted into the
desired targeting vector, expresses sequence specific ssDNA rather than
RNA. The ssDNA (1) can be regulated to express ssDNA at therapeutic but
subtoxic levels, (2) is sequence specific and possesses a relatively long
half-life, and (3) can be targeted to multiple sites on a target RNA or be
targeted to multiple target RNAs.
The results of the research will be published in the near future in a
peer-reviewed journal. CYGS is negotiating to (1) acquire certain
therapeutic sequences to incorporate into a product, and (2) license their
enabling technology to owners of patented gene sequences. Either way,
combining the above technologies promises to overcome the industry-wide
obstacle currently preventing the practical application of antisense
therapies.
This conference is held to address the solution of Antisense delivery
and gene therapy to peers in the industry.
ADDITIONAL INFORMATION
Recent articles of the increasing popularity of gene research and
Antisense therapeutics:
January 4, 2000 biz.yahoo.com
Decision Resources Predicts That the Next Decade Will Be an Exciting Time
for Those With a Stake in Antisense Therapeutics
December 27,1999
dailynews.yahoo.com
Gene Research Shares Soar on High Hopes
Profile on CYGS: pennyprofiles.com
A simplified explanation of CYGS's technology and forthcoming
developments.
Detailed specifics of CYGS and its technology can be found on their web
site at:
cygs.net
The sheer development of the industry over the last 10 years suggest that
the role of Bio-genetics, as a competing standard for the future of modern
medicine is progressing. With gene therapy at the root of almost any
potential viral infection or genetic inheritance of progressive diseases,
we believe that CYGS is in a position to play a major role in its specific
industry. It represents one of our core long-term position plays.
Mic@PennyProfiles PennyProfiles- Stock hunters
pennyprofiles.listbot.com
pennyprofiles.com
DISCLAIMER:
Penny Profiles is not compensated in any way for any research or
compilation of information in regards to Cryogenics Solutions, Inc., and
merely distribute this information as a supplement to your own research as
requested by our members. All investors and potential investors should
take the time to educate themselves to the industry in general and should
address and confirm any specifics by contacting the company or reviewing
the company's web site at: cygs.net before
making any investment decisions. Penny Profiles makes no recommendations
and encourages everyone to do their own due diligence!! We are not
responsible for the results of your trading decisions. Nothing in this
email shall constitute a solicitation or an offer to buy or sell any
securities here in.
Good trading,
Mic@PennyProfiles pennyprofiles.com
|
